Ran Ji
Authored Items
Dirk Schadendorf, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario MandalĂ , MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, MD, PhD, Reinhard Dummer, MD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
November 2018 Vol 9, NO 11
Adjuvant treatment (tx) of resected stage III BRAF-mutant melanoma with dabrafenib + trametinib (D+T) significantly reduced the risk of recurrence vs placebo (PBO).
Last modified: November 15, 2018